Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 58Filgrastim 37Radiotherapy 31Busulfan 28fludarabine phosphate 26Antilymphocyte Serum 25Cyclosporine 24Peripheral Blood Stem Cell Transplantation 23Etoposide 22Methotrexate 20Melphalan 18Mycophenolic Acid 17Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Vincristine 13Cytarabine 13Tacrolimus 12Rituximab 11Whole-Body Irradiation 9Thiotepa 9Prednisone 9Doxorubicin 8Leucovorin 7sargramostim 6aldesleukin 6Granulocyte Colony-Stimulating Factor 6Psychiatric Rehabilitation 5Daunorubicin 5pembrolizumab 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Fenofibrate × Sarcoma × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡